These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38359910)

  • 1. Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of Levodopa-induced dyskinesias.
    Ribeiro DL; Guimarães RP; Bariotto-Dos-Santos K; Del Bel E; Padovan-Neto FE
    Eur J Neurosci; 2024 Apr; 59(7):1604-1620. PubMed ID: 38359910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    F Hernández L; Castela I; Ruiz-DeDiego I; Obeso JA; Moratalla R
    Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
    Castela I; Casado-Polanco R; Rubio YV; da Silva JA; Marquez R; Pro B; Moratalla R; Redgrave P; Costa RM; Obeso J; Hernandez LF
    Neurobiol Dis; 2023 Jan; 176():105930. PubMed ID: 36414182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
    Huang YT; Chen YW; Lin TY; Chen JC
    Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
    Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Belujon P; Lodge DJ; Grace AA
    Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
    Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
    Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
    Rentsch P; Egan T; Kuriakose A; Stayte S; Vissel B
    J Neurochem; 2023 Dec; 167(5):633-647. PubMed ID: 37916541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
    Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of the histamine H
    Avila-Luna A; Ríos C; Gálvez-Rosas A; Montes S; Arias-Montaño JA; Bueno-Nava A
    Psychopharmacology (Berl); 2019 Jun; 236(6):1937-1948. PubMed ID: 30762089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.